MdmX Protects p53 from Mdm2-Mediated Degradation

per Jackson, Mark W., Berberich, Steven J.
Publicat 2000

HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss

per Bartel, Courtney A., Jackson, Mark W.
Publicat a PLoS One (2017)

Silencing the Roadblocks to Effective Triple Negative Breast Cancer Treatments by siRNA Nanoparticles

per Parvani, Jenny G., Jackson, Mark W.
Publicat a Endocr Relat Cancer (2017)

The Critical, Clinical Role of Interferon-Beta in Regulating Cancer Stem Cell Properties in Triple-Negative Breast Cancer

per Doherty, Mary R., Jackson, Mark W.
Publicat a DNA Cell Biol (2018)

Using interferon-beta to combat cancer stem cell properties in triple negative breast cancer

per Doherty, Mary R., Jackson, Mark W.
Publicat a Oncoscience (2018)

c-MYC Functions as a Molecular Switch to Alter the Response of Human Mammary Epithelial Cells to Oncostatin M

per Kan, Charlene E., Cipriano, Rocky, Jackson, Mark W.
Publicat 2011

Potent EMT and CSC Phenotypes are Induced by Oncostatin-M in Pancreatic Cancer

per Smigiel, Jacob M., Parameswaran, Neetha, Jackson, Mark W.
Publicat a Mol Cancer Res (2017)

Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics

per Smigiel, Jacob M., Parameswaran, Neetha, Jackson, Mark W.
Publicat a Cancers (Basel) (2018)

ETV1 positively regulates transcription of tumor suppressor ARF

per Zynda, Evan, Jackson, Mark W, Bhattacharya, Partho, Kandel, Eugene S
Publicat 2013

HiJAK’d Signaling; the STAT3 Paradox in Senescence and Cancer Progression

per Junk, Damian J., Bryson, Benjamin L., Jackson, Mark W.
Publicat 2014

Constitutive CCND1/CDK2 Activity Substitutes for p53 Loss, or MYC or Oncogenic RAS Expression in the Transformation of Human Mammary Epithelial Cells

per Junk, Damian J., Cipriano, Rocky, Stampfer, Martha, Jackson, Mark W.
Publicat 2013

FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance

per Bartel, Courtney A., Parameswaran, Neetha, Cipriano, Rocky, Jackson, Mark W.
Publicat a Oncotarget (2016)

STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence

per Bryson, Benjamin L., Junk, Damian J., Cipriano, Rocky, Jackson, Mark W.
Publicat a Cell Cycle (2016)

Rb/E2F4 and Smad2/3 Link Survivin to TGF-β-induced Apoptosis and Tumor Progression

per Yang, Jiayi, Song, Kyung, Krebs, Tracy L., Jackson, Mark W., Danielpour, David
Publicat 2008

Cancer Stem Cell Plasticity Drives Therapeutic Resistance

per Doherty, Mary R., Smigiel, Jacob M., Junk, Damian J., Jackson, Mark W.
Publicat a Cancers (Basel) (2016)

TGF-β signaling engages an ATM-CHK2-p53–independent RAS-induced senescence and prevents malignant transformation in human mammary epithelial cells

per Cipriano, Rocky, Kan, Charlene E., Graham, James, Danielpour, David, Stampfer, Martha, Jackson, Mark W.
Publicat 2011

Tumor Microenvironmental Signaling Elicits Epithelial-Mesenchymal Plasticity through Cooperation with Transforming Genetic Events

per Junk, Damian J, Cipriano, Rocky, Bryson, Benjamin L, Gilmore, Hannah L, Jackson, Mark W
Publicat 2013

Coordinated regulation of p31(Comet) and Mad2 expression is required for cellular proliferation

per Date, Dipali A, Burrows, Amy C, Venere, Monica, Jackson, Mark W, Summers, Matthew K
Publicat 2013

Balancing STAT Activity as a Therapeutic Strategy

per Polak, Kelsey L., Chernosky, Noah M., Smigiel, Jacob M., Tamagno, Ilaria, Jackson, Mark W.
Publicat a Cancers (Basel) (2019)

Mutagenesis by reversible promoter insertion to study the activation of NF-κB

per Kandel, Eugene S., Lu, Tao, Wan, Youzhong, Agarwal, Mukesh K., Jackson, Mark W., Stark, George R.
Publicat 2005